S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Krystal Biotech Stock Forecast, Price & News

-2.63 (-6.20%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
251,221 shs
Average Volume
137,638 shs
Market Capitalization
$885.29 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Krystal Biotech logo

About Krystal Biotech

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It also involves in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.


Krystal Biotech (NASDAQ:KRYS) Sees Strong Trading Volume
November 24, 2021 |  americanbankingnews.com
Krystal Biotech (NASDAQ:KRYS) Reaches New 52-Week Low at $41.29
November 23, 2021 |  americanbankingnews.com
Krystal Biotech (NASDAQ:KRYS) Stock Price Down 5.7%
November 22, 2021 |  americanbankingnews.com
Krystal Biotech (NASDAQ:KRYS) Shares Gap Up to $51.31
November 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$18.36 per share


Net Income
$-32.17 million
Pretax Margin




Free Float
Market Cap
$885.29 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.25 out of 5 stars

Medical Sector

331st out of 1,391 stocks

Biological Products, Except Diagnostic Industry

53rd out of 201 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech
or view top-rated stocks.

How has Krystal Biotech's stock price been impacted by Coronavirus?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KRYS stock has decreased by 20.3% and is now trading at $39.81.
View which stocks have been most impacted by COVID-19

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Krystal Biotech

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings results on Sunday, November, 7th. The company reported ($0.70) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.76) by $0.06.
View Krystal Biotech's earnings history

What price target have analysts set for KRYS?

5 brokerages have issued 1-year price targets for Krystal Biotech's shares. Their forecasts range from $90.00 to $103.00. On average, they anticipate Krystal Biotech's stock price to reach $96.67 in the next year. This suggests a possible upside of 142.8% from the stock's current price.
View analysts' price targets for Krystal Biotech
or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:
  • Krish S. Krishnan, Chairman, President & Chief Executive Officer
  • Suma M. Krishnan, Chief Operating Officer & Director
  • Stacie Oliver, Clinical Affairs Scientist
  • George Chen, Manager-Information Technology & CSV
  • Trevor Parry, Senior Director-Scientific Affairs

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.94%), Lord Abbett & CO. LLC (4.81%), Credit Suisse AG (3.48%), Point72 Asset Management L.P. (2.40%), Geode Capital Management LLC (1.43%) and Hood River Capital Management LLC (1.02%).
View institutional ownership trends for Krystal Biotech

Which major investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Citigroup Inc., Morgan Stanley, Hood River Capital Management LLC, Citadel Advisors LLC, and Voya Investment Management LLC.
View insider buying and selling activity for Krystal Biotech
or view top insider-selling stocks.

Which major investors are buying Krystal Biotech stock?

KRYS stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Verition Fund Management LLC, Ensign Peak Advisors Inc, Renaissance Technologies LLC, Marshall Wace LLP, Millennium Management LLC, UBS Group AG, and ACT Capital L.L.C..
View insider buying and selling activity for Krystal Biotech
or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $39.81.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $885.29 million. The company earns $-32.17 million in net income (profit) each year or ($2.71) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 75 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

Where are Krystal Biotech's headquarters?

Krystal Biotech is headquartered at 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at (412) 586-5830 or via email at [email protected].

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.